RecruitingPhase 2NCT03866382
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Studying Adenocarcinoma of the penis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Andrea B ApoloAlliance for Clinical Trials in Oncology
- Intervention
- Biospecimen Collection(procedure)
- Enrollment
- 314 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2027
Study locations (30)
- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
- Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
- Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
- Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
- Alaska Women's Cancer Care, Anchorage, Alaska, United States
- Anchorage Oncology Centre, Anchorage, Alaska, United States
- Katmai Oncology Group, Anchorage, Alaska, United States
- Providence Alaska Medical Center, Anchorage, Alaska, United States
- Kingman Regional Medical Center, Kingman, Arizona, United States
- Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
- Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
- Mayo Clinic in Arizona, Scottsdale, Arizona, United States
- University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona, United States
- Banner University Medical Center - Tucson, Tucson, Arizona, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03866382 on ClinicalTrials.govOther trials for Adenocarcinoma of the penis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT05639972E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated CancersChristian Hinrichs
- RECRUITINGPHASE1NCT07118176Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic CancersJonsson Comprehensive Cancer Center
- RECRUITINGPHASE2NCT06683846Ivonescimab in the Treatment of Multiple Advanced TumorsFudan University
- RECRUITINGPHASE2NCT05686226E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated CancersChristian Hinrichs
- ACTIVE NOT RECRUITINGPHASE2NCT03333616Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary TumorsDana-Farber Cancer Institute
- ACTIVE NOT RECRUITINGPHASE1NCT02496208Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary TumorsNational Cancer Institute (NCI)